U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549269) titled 'Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis' on April 09.
Brief Summary: Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used. However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.
Study Start Date: Dec. 01, 2019
Study Type: OBSERVATIONAL
Condition:
Esophageal Cancer
Recruitment...